• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mallinckrodt faces probe over price hikes for injectable pain-killer

May 30, 2017 By Sarah Faulkner

Mallinckrodt PharmaceuticalsSen. Claire McCaskill (D-Mo.) penned a letter to Mallinckrodt Pharmaceuticals (NYSE:MNK) last week, probing for details about the company’s pricing strategies for its injectable pain-killer, Ofirmev.

Mallinckrodt acquired Ofirmev in 2014, when it bought Cadence Pharmaceuticals in a $1.4 billion deal. In May of that year, Mallinckrodt hiked the pain-killer’s list price from $14.75 per vial to $35.40 per vial.

McCaskill pointed to reports showing that the company’s price increases cost hospitals millions, which may have pushed healthcare practitioners to use cheaper painkillers, including highly addictive opioids.

The senator wrote that she is also investigating the actions by top opioid manufacturers to better understand how they market their products.

She requested that Mallinckrodt provide her with quarterly sales data for Ofirmev from before and after the company acquired the injectable acetaminophen formulation. McCaskill also asked for published data showing that Ofirmev is an effective alternative to opioids as a pain management therapy.

Mallinckrodt has been widely criticized for its pricing strategies – 1 of its top-selling products is a multiple sclerosis treatment that comes with a price-tag of more than $30,000 per vial.

But the drugmaker defended itself in response to McCaskill’s probe, saying that the increase to Ofirmev’s list price was to “stabilize” the product’s financial situation and stop it from losing “tens of millions of dollars annually”. It also pointed to customer discount opportunities and investments the company has made to demonstrate the pain-killers’ value.

“These studies reinforce Mallinckrodt’s commitment to providing hospital customers with high-value products that address the clinical needs of patients,” the company wrote.

Mallinckrodt said it has and will continue to cooperate with McCaskill’s investigation.

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Mallinckrodt Pharmaceuticals

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS